SK Bioscience and Seoul National University Hospital Collaborate on COVID-19 Vaccine Clinical Trials

[Asia Economy Reporter Cho Hyun-ui] SK Bioscience announced on the 2nd that it has signed a business agreement with Seoul National University Hospital to conduct a Phase 1 clinical trial of its COVID-19 vaccine candidate 'NBP2001.'

Under this agreement, Seoul National University Hospital will initiate the Phase 1 clinical trial by administering NBP2001 to subjects to evaluate its safety and immunogenicity in the body. Professor Oh Myung-don of the Department of Infectious Diseases at Seoul National University Hospital and Professor Kim Ui-seok of the Department of Infectious Diseases at Bundang Seoul National University Hospital will serve as principal investigators.

Kim Yeon-su, director of Seoul National University Hospital, stated, “We plan to actively support medical staff so that they can devote themselves to researching effective and safe vaccines and treatments.”

SK Bioscience plans to successfully conduct Phase 1 in collaboration with Seoul National University Hospital while also preparing for subsequent clinical trials.

SK Bioscience CEO Ahn Jae-yong said, “We look forward to thoroughly verifying the safety and immunogenicity of NBP2001 in cooperation with the excellent research teams at Seoul National University Hospital and promptly proceeding with follow-up clinical trials.”

This content was produced with the assistance of AI translation services.